Low L-selectin (CD62L) expression in acute myeloid leukemia correlates with a bad cytogenetic risk

European Journal of Haematology

Volumn 71, Issue 5, 2003, Pages 366-376

  Graf, M ^a   Reif, S ^b   Hecht, K ^a   Pelka Fleischer, R ^a   Pfister, K ^c   Nuessler, V ^a,d   Schmetzer, H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute myeloid leukemia; Adhesion molecules; I selectin; Immunophenotyping; Prognosis

Indexed keywords

ANTIBODY; CELL SURFACE RECEPTOR; CYTARABINE; CYTOKINE; CYTOTOXIC AGENT; DAUNORUBICIN; FLUORESCEIN ISOTHIOCYANATE; L SELECTIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; L-SELECTIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM PROTEINS; REMISSION INDUCTION; RISK; THIOGUANINE; TREATMENT OUTCOME; TRETINOIN; TUMOR STEM CELLS;

EID: 0142217319     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00140.x     Document Type: Article

References (21)

1. SACKSTEIN R. Expression of an L-selectin ligand on hematopoietic progenitor cells. Acta Haematol 1991;91:22-28.
2. KORTLEPEL K, BENDALL LJ, GOTTLIEB DJ. Human acute myeloid leukemia cells express adhesion proteins and bind bone marrow fibroblast monolayers and extracellular matrix proteins. Leukemia 1993;7:1174-1179.
3. REUSS-BORST MA, KLEIN G, WALLER HD, MÜLLER CA. Differential expression of adhesion molecules in acute leukemia. Leukemia 1995;9:869-874.
4. LIESVELD JL. Expression and function of adhesion receptors in acute myelogenous leukemia: parallels with normal erythroid and myeloid progenitors. Acta Haematol 1997;97:53-62.
5. DE WAELE M, RENMANS W, JOCHMANS K, et al. Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts. Eur J Haematol 1999;63:192-201.
6. MOHLE R, MOORE MA, NACHMAN RL, RAFII S. Transendothelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line. Blood 1997;89:72-80.
7. BRUSERUD O, ULVERSTAD E. Expression and release of adhesion molecules by human acute myelogenous leukemia blasts. Leuk Res 1999;23:149-157.
8. EXTERMAN M, BACCHI M, MONAI N, FOPP M, FEY M, TICHELLI A, SCHAPIRA M, SPERTINI O. Relationship between cleaved L-selectin levels and the outcome of acute myeloid leukemia. Blood 1998;92:3112-3115.
9. BENNETT JM, CATOVSKY D, DANIEL MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:626-629.
10. BENE MC, BERNIER M, CASTOLDI G, KNAPP W, LUDWIG WD, MATUTES E, ORFAO A, VAN'T VEER MB for the European Group for the Immunological Classification of Leukemias (EGIL). Proposals for the immunological classification of acute leukaemias. Leukemia 1995;9:1783-1788.
11. ROTHE G, SCHMITZ G (working group on flow cytometry and image analyses). Consensus protocol for the flow cytometric immunophenotying of hematopoietic malignancies. Leukemia 1996;10:877-895.
12. MITELMAN K. ISCN: An International System for Human Cytogenetic Nomenclature. Basel: Karger, 1995.
13. MROZEK K, HEINONEN K, DE LA CHAPELLE A, BLOOMFIELD CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17-31.
14. MAZUMDAR M, GLASSMAN JR. Tutorial in biostatistics. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatment. Statist Med 2000;19:113-132.
15. REIF S, WIESNER D, DUELL T, MITTERMUELLER J, SCHMETZER H. Not the presence but the amount of clonal DNA detectable in remission of acute myeloid leukemia (AML) is predictive for relapse. Eur J Haematol 2001;67:207-222.
16. MACEDO A, ORFAO A, MARTINEZ A, VALVERDE B, LOPEZ-BERGES MC, SAN MIGUEL JF. Immunophenotype of c-kit in normal human bone marrow: implications for the detection of minimal residual disease in AML. Br J Haematol 1995;89:338-341.
17. PRATT G, RAWSTRON AC, ENGLISH AE, JOHNSON RJ, JACK AS, MORGAN GJ, SMITH GM. Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell does, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 2001;114:937-943.
18. KAWAISHI K, KIMURA A, KATOH O, SASAKI A, OGUMA N, IHARA A, SATOW Y. Decreased L-selctin expression in CD34-positive cells from patients with chronic myelocytic leukemia. Br J Haematol 1996;93:367-374.
19. ROWE JM, LIESVELD JL. Hematopoietic growth factors and acute leukemia. In: TALLMAN MS, GORDON LI, Eds. Diagnostic and Therapeutic Advances in Hematologic Malignancies. Boston: Kluwer Academic Publishers, 1999:40-43.
20. SPERTINI O, CALLEGARI P, CORDAY A, HAUERT J, JOGGI J, von FLIEDNOR V, SCHAPIRA M. High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast adhesion to activated endothelium. Blood 1994;84:1249-1256.
21. SCHLEIFFENBAUM B, SPERTINI O, TEDDER T. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 1992;119:229-238.